Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Pans Pomalidomide For Blood Cancer, Backs Xarelto In ACS Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. HTA rejects Celgene’s pomalidomide for treating multiple myeloma on cost grounds but waves through Bayer’s rivaroxaban for preventing blood clots in people who have had a heart attack.

You may also be interested in...



Celgene To Launch Pomalyst At $10,500 Per Treatment Cycle

FDA approved the immunomodulator Feb. 8 for multiple myeloma patients who have failed at least two prior therapies, including lenalidomide and bortezomib.

Xarelto, Pradaxa Difficult To Separate After Positive NICE Final Guidance

Bayer’s Xarelto has made it into the NHS in England after its NICE recommendation went unchallenged, prompting a head to head battle with Boehringer Ingelheim’s Pradaxa.

In Initial Assessments, NICE Recommends Celgene's Thalidomide And J&J's Bortezomib

Thalidomide and bortezomib could be recommended for in multiple myeloma, but NICE rejects Novartis' Xolair for children with severe allergic asthma.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel